Strong preclinical data on FG001’s potential in guiding surgical removal of pancreatic cancer has been accepted for presentation on the World Molecular Imaging Congress 2019
August 20, 2019
FluoGuide A/S’s (“FluoGuide”) compound FG001 lights up the cancer and has demonstrated potential to vastly improve the radicality of surgery in preclinical studies. FG001 use is initially focused on glioblastoma, butFluoGuide is pleased to announce that data, confirming FG001’s potential in also guiding surgical removal of pancreatic cancer, will be presented at the World Molecular Imaging Congress 2019 (WMIC) in Montreal, on 4-7 September 2019.
FG001 is initially focused on guiding glioblastoma surgery but has potential in several other cancer indications. One of these indications is pancreatic cancer, where strong preclinical data was already communicated in connection with the company’s IPO process in April 2019. The company is pleased to announce that this data has been accepted by the scientific community for presentation at the World Molecular Imaging Congress 2019. This acknowledgement of the data is an important milestone for FluoGuide as it underlines the potential of uPAR targeted products in guiding cancer surgery in a range of cancer indications, including glioblastoma, breast, colorectal, head & neck and pancreatic cancer.
The study to be presented was finalized during the first half of 2019 with the aim to evaluate the value of FG001 for resection of the primary tumor and metastases in an orthotopic human xenograft pancreatic cancer model and also to investigate if fluorescent-guided imaging could locate additional metastases after conventional removal of metastasis under normal surgery in white light.
The data demonstrated a benefit of using intraoperative fluorescent guidance and additional metastases were identified compared to using normal white light surgery. On a subject basis, in 4 out of 8 mice (50%) there were identified additional metastases with the uPAR targeted optical probe. FG001 enabled intraoperative optical cancer imaging, including robotic surgery, and may be a benefit during intended radical resection of disseminated pancreas cancer by finding more metastases than with traditional white light surgery.
The data on FG001’s potential of improving the obtained radicality of surgery will be presented at the World Molecular Imaging Congress 2019 (WMIC) in Montreal, Canada, 4-7 September 2019. The presentation is titled “Improved surgical resection of metastatic pancreatic cancer using uPAR targeted in vivo fluorescent guidance: comparison with traditional white light surgery” and will be presented by PhD student Karina Juhl from Rigshospitalet and University of Copenhagen.
Andreas Kjær, in charge of research at FluoGuide, comments:
“We are very happy that this promising data has been selected for presentation at WMIC, an important society within molecular imaging and surgical guidance. Optical targeting of uPAR is likely to become of benefit to patients and surgeons in several cancer indications and this presentation is an important event to highlight the technology’s potential.”
Morten Albrechtsen, CEO of FluoGuide, comments:
“We are positive that presentation of the data will contribute to the understanding that uPAR is a highly interesting target and can lead FluoGuide to a leading position in the field of guiding cancer surgery”.
About the World Molecular Imaging Congress (WMIC)
The World Molecular Imaging Congress (WMIC) is organized by the World Molecular Imaging Society (WMIS) widely recognized expertise in molecular imaging. WMIC was established in 2011 by integrating the Academy of Molecular Imaging and the Society for Molecular Imaging into a single streamlined society focused on advancing the field of molecular imaging (MI).
For further information about FluoGuide, please contact:
Morten Albrechtsen, CEO, FluoGuide A/S
Telephone: +45 24 25 62 66
FluoGuide A/S provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product, FG001, improves precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. FG001 is made of a cancer targeting molecule linked to a fluorophore. The FluoGuide products is expected to reduce the suffering of patients and increase the likelihood of cure. They can also reduce costs for the health care system and thus benefit society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial.
The potential of FluoGuide goes beyond FG001 and cancer surgery. FluoGuide is listed on Spotlight Stock Market (ticker: FLUO)
FG001, FluoGuide’s first product, lights up the cancer and its invasive growth into the surrounding tissue. It helps the surgeon remove the entire tumor during surgery and increases the chance for complete cure of the patient. The task for the surgeon is simply to “turn the lights on and see the entire tumor”. The solution helps surgeons remove a minimal amount of normal tissue while also reducing the risk of leaving cancer tissue behind. This reduces the suffering of the patient and increases the likelihood of cure, and also reduces costs for the health care system. FG001 is currently prepared for a proof-of-concept clinical study.